Biogen Stock News

Value plays look to have dried up during the past few sessions that account for the front end of the Santa Claus Rally.

The rumor mill is grinding hard with the company, which, according to a newspaper report, is in talks to be acquired.

4.05pm: Dow up for the sixth straight session     US stocks finished the trading session mixed as the Dow and S&P 500 neared all-time highs. At the close, the Dow gained 90 points to 36,489, while

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Buy Now According to the report analysis, Global Autoimmune Disorder Drug Delivery Device Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027 states that AbbVie Inc., Bayer AG, Novartis AG, Amgen Inc., Merck KGaA, F. Hoffmann- La Roche Ltd., Teva Pharmaceutical Industries Ltd., Biogen Inc., GlaxoSmithKline Plc, Johnson Read More » The post Global Autoimmune Disorder Drug Delivery Device Market Is Predicted To Propel Owing To Surging Adoption Of Advanced Drug Delivery Devices: Ken Research appeared first on Ken Research .

Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.

Independent Advisor Alliance raised its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 9.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,400 shares of the biotechnology companys stock after acquiring an additional 123 shares during the period. Independent Advisor Alliances holdings in Biogen were worth $396,000 []

Related Stocks: TMUS , JCI , NOC , JNJ , ISRG , IRWD , INTU , BAC , AMD , ORLY , MRNA , VNO , ATVI , NXPI , COST , ON , BIIB , LLY , AMAT , DG , BRK.B , BXP , ICE , HIG ,

The market is being driven by a growing senior population, increased awareness of ALS, and an increasing incidence rate. The high cost of ALS therapy, on the other hand, may be an obstacle to the market throughout the projection period. North

Biogen Inc. (NASDAQ:BIIB) Equities research analysts at Wedbush upped their Q1 2022 earnings estimates for Biogen in a report released on Monday, December 20th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings per share of $3.54 for the quarter, up from their previous estimate of $3.13. Wedbush also issued [] The post Q1 2022 Earnings Estimate for Biogen Inc. (NASDAQ:BIIB) Issued By Wedbush appeared first on ETF Daily News .

Biogen Inc. (NASDAQ:BIIB) William Blair increased their Q4 2021 earnings per share estimates for Biogen in a report released on Monday, December 20th. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings of $3.56 per share for the quarter, up from their prior forecast of $3.12. William Blair also [] The post William Blair Research Analysts Lift Earnings Estimates for Biogen Inc. (NASDAQ:BIIB) appeared first on ETF Daily News .

TOKYO, Dec 24, 2021 (JCN Newswire) Eisai Co., Ltd. and Biogen Inc. announced The post Investigational Alzheimers Disease Therapy Lecanemab Granted FDA Fast Track Designation first appeared on IT Business Net .

Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , PRLD , NTRA , ANTM , AFIB , ABCL , DCPH , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,

TOKYO and CAMBRIDGE, Mass. , Dec. 23, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (NASDAQ: BIIB , Corporate headquarters: Cambridge, Massachusetts , CEO: Michel Vounatsos , ", Biogen", )) announced today that lecanemab, an investigational anti-amyloid beta (A) protofibril antibody for the treatment of early Alzheimer''s disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). FDA granted Breakthrough Therapy designation for lecanemab in June of 2021. Breakthrough Therapy designation and Fast Track designation are two FDA programs that are intended to facilitate and expedite development of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition such as AD and provide opportunities for frequent interactions with the FDA.. In September 2021 , Eisai initiated a rolling submission to the FDA of a Biologics License application (BLA) for lecanemab under the accelerated approval pathway.